When you want a PGA
don’t compromise Lumigan Logo

Whenever you need to prescribe a PGA, consider LUMIGAN® 0.01% for proven IOP-lowering power and tolerability.1

IOP=intraocular pressure;

PGA=prostaglandin analog.

Whenever you need to prescribe a PGA, consider LUMIGAN® 0.01% for proven IOP-lowering power and tolerability.1

IOP=intraocular pressure;

PGA=prostaglandin analog.

Efficacy

Designed for powerful efficacy with less active ingredient1,*

*Compared with bimatoprost 0.03%.

In a clinical study, LUMIGAN® 0.01% demonstrated2:

  • Equivalent IOP-lowering efficacy compared with bimatoprost 0.03%
  • Consistent IOP reduction over 12 months, at all time points
  • Mean IOP <18 mm Hg at all time points from Week 2 to Month 12
Up to
31%

mean IOP reduction from baseline with 67% less active ingredient than bimatoprost 0.03% (8 AM, Month 3)2

FULL EFFICACY DATA STUDY DESIGN
Approximately
80%

of patients achieved ≥20% reduction in IOP from baseline (8 AM, Month 12)2

IOP=intraocular pressure.

Mechanism of Action

LUMIGAN® 0.01% is a different type of prostaglandin analog1,3

  • LUMIGAN® 0.01% is a prostamide that binds to prostamide receptors3

Tolerability

Designed for an improved side-effect profile2,4*

*Compared with bimatoprost 0.03%.

LUMIGAN® 0.01% had 25% fewer overall treatment-related AEs compared with bimatoprost 0.03%4,†

  • Conjunctival hyperemia was the most common AE in this trial4
    • 31.4% with LUMIGAN® 0.01% (n=58/185) vs 39.0% with bimatoprost 0.03% (n=73/187)

AE=adverse event.

†One or more treatment-related AEs (overall) were reported for 38.4% (n=71/185) of patients receiving LUMIGAN® 0.01% and 50.8% (n=95/187) of patients receiving bimatoprost 0.03% (P=0.030).4

STUDY DESIGN

Patient satisfaction

80.3% of patients (n=171) were very or extremely willing to continue with LUMIGAN® 0.01% after 12 months of treatment2

Patients rated on a 4-point scale (0=not willing, 1=somewhat willing, 2=very willing, 3=extremely willing).2

80.3% of patients were very or extremely willing to continue

Patients rated on a 4-point scale (0=not willing, 1=somewhat willing, 2=very willing, 3=extremely willing).2

Dosing

Starting patients on LUMIGAN® 0.01%1

LUMIGAN® 0.01% dosing is one drop in the affected eye(s) once-daily in the evening.

May be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Find resources for technicians and office staff

Access patient savings, pharmacy callback
guides, and patient counseling resources.

Join The Alliance

Instructions for applying eye drops

Step One Visual

Step 1

Wash your hands. Tilt your head back and look at the ceiling.

  • If you wear contact lenses, remove them first, then wait 15 minutes after using your eye drops to put them back into your eyes.
Step Two Visual

Step 2

Using your index finger, pull down your lower eyelid to form a pocket.

Step Three Visual

Step 3

Gently squeeze 1 drop into the pocket. Don’t let the bottle tip touch your eye, your fingers, or anything else.

Step Four Visual

Step 4

Gently close your eyes and lightly press on the inside corners of your eyes.

Step Five Visual

Step 5

Carefully blot away any excess liquid that may be on your skin.

Access and Savings

Eligible commercially-insured patients may pay as little as

$15‡ per 90-day prescription fill

That's as little as $5 a month for a 90-day supply

Enroll your patient

Patients can also call 1-833-DIAL-AYS (1-833-342-5297) or text SAVINGS to 72428§

‡Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for LUMIGAN® 0.01%, COMBIGAN®, or ALPHAGAN® P 0.1%. Offer not valid for patients enrolled in Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See At Your Service Savings Program Terms, Conditions, and Eligibility Criteria at SaveWithAYS.com.

§AYS Alerts: Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer. View our Mobile Terms & Conditions and Privacy Policy.

Need help with prior authorizations?

ABBVIEACCESS has you covered
Find Support

References

  1. LUMIGAN® (bimatoprost ophthalmic solution) 0.01% Prescribing Information.
  2. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):661–671.
  3. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741–764.
  4. Data on file, Allergan, 2007; 192024-031.

INDICATION

LUMIGAN® 0.01% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

LUMIGAN® 0.01% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.

WARNINGS AND PRECAUTIONS

Pigmentation

Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. While treatment with LUMIGAN® 0.01% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes

LUMIGAN® 0.01% may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation

Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. In addition, because these products may exacerbate inflammation, caution should be used in patients with active intraocular inflammation (e.g., uveitis).

Macular Edema

Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. LUMIGAN® 0.01% should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Bacterial Keratitis

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

Contact Lens Use

LUMIGAN® 0.01% contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to instillation of LUMIGAN® 0.01% and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS

In a 12-month clinical study with bimatoprost ophthalmic solutions 0.01%, the most common adverse reaction was conjunctival hyperemia (31%). Approximately 1.6% of patients discontinued therapy due to conjunctival hyperemia. Other adverse drug reactions (reported in 1 to 4% of patients) with LUMIGAN® 0.01% in this study included conjunctival edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, erythema of eyelid, eyelids pruritus, growth of eyelashes, hypertrichosis, instillation site irritation, punctate keratitis, skin hyperpigmentation, vision blurred, and visual acuity reduced.

USE IN SPECIFIC POPULATIONS

Pediatric Use

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/
lumigan_pi.pdf